Wisconsin Alumni Research Foundation

Drug Discovery
Drug Discovery
Production of Packaged DNA Sequence
WARF: P05033US

Inventors: Paul Ahlquist, Paul Lambert, Dohun Pyeon

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method that makes easy and efficient generation of infectious HPV possible for the first time.
Overview
Human Papillomavirus (HPV), the causative agent of cervical cancer, is the most common sexually transmitted pathogen. However, the amount of infectious papillomavirus available for research is greatly limited because current methods of producing the virions are technically demanding, time-consuming and variable; produce relatively low yields; and require access to specific cell/tissue types.
The Invention
UW-Madison researchers have developed a method for packaging the full papillomaviral genome into HPV virions in transfected mammalian cells, making easy and efficient generation of infectious HPV possible for the first time. A DNA sequence containing a full-length or nearly full-length papillomaviral genome is selected and preferably cloned and amplified in an appropriate plasmid. The genome sequence is then isolated from the plasmid and recircularized before it is co-transfected with an HPV capsid sequence into a suitable mammalian cell. Finally, the resulting infectious viral particles are purified. Either the papillomaviral genome or the HPV capsid sequence may be modified before packaging.
Applications
  • Enables the development of neutralization assays for vaccine development and production
  • May lead to the creation of model systems for testing the efficacy of drugs, gene therapy, and other potential treatment regimens
  • Also enables the development and refinement of diagnostic tests for HPV
  • Makes possible previously unapproachable studies of papillomavirus-host interactions
  • May lead to the identification of novel therapeutic targets
Key Benefits
  • Infectious HPV can be easily and efficiently generated within days.
  • Any desired mutation can be incorporated into the papillomaviral DNA.
  • Produces over 1000 times more infectious virus than current methods
  • Useful in basic, pre-clinical and clinical research
  • Independent of viral DNA replication and epithelial differentiation
  • Genome sequence and capsid sequence do not need to be from the same strain of HPV.
  • Also suitable for animal papillomaviral genome sequences
Additional Information
For More Information About the Inventors
For current licensing status, please contact Jennifer Gottwald at [javascript protected email address] or 608-960-9854

WARF